Evidence map›Paper›PMID 40041628›Full record

ArticleCureus2025

The Real-World Impact of Long-Acting Injectable Cabotegravir-Rilpivirine on Weight and Renal Function.

Lukas McNaboe, Alvaro Ayala, Julia Kostka, Dorothy Wakefield, Lisa Chirch

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lukas McNaboeDepartment of Medicine, University of Connecticut, Farmington, USA.
Alvaro AyalaDepartment of Medicine, University of Connecticut, Farmington, USA.
Julia KostkaDepartment of Medicine, Division of Infectious Diseases, University of Connecticut, Farmington, USA.
Dorothy WakefieldStatistics, Saint Francis Hospital and Medical Center, Hartford, USA.
Lisa ChirchDepartment of Medicine, Division of Infectious Diseases, University of Connecticut, Farmington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the continued advancement in the efficacy and convenience of antiretroviral therapy (ART), counseling patients about the metabolic side effects of medications remains an integral task for clinicians. This retrospective study examines changes in weight and renal function in patients receiving long-acting injectable cabotegravir-rilpivirine (LAI CAB/RPV) compared to oral regimens in a real-world setting. In this small set of patients, LAI CAB/RPV led to less weight gain compared to oral integrase inhibitor-based regimens. However, there was no significant change in the estimated glomerular filtration rate (eGFR) between patients who were started on LAI CAB/RPV and those who continued to receive oral regimens with or without tenofovir alafenamide (TAF).

Indexed as

antiretroviral therapy and human immunodeficiency viruscabotegravir rilpivirinemedication induced weight gainnon-randomized observational datarenal function

Identifiers

PMID40041628
PMCPMC11879144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.